Literature DB >> 11676178

Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats.

H Marumo1, K Satoh, A Yamamoto, S Kaneta, K Ichihara.   

Abstract

Effects of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, simvastatin and atorvastatin, on diltiazem-induced hypotension were examined in anaesthetized rats and compared to that of pravastatin. Vehicle, 2 mg/kg/day simvastatin, 2 mg/kg/day atorvastatin, or 4 mg/kg/day pravastatin was administered orally for 4 days. Diltiazem at 3 mg/kg was given orally 2 hours after the final administration of the inhibitors. Arterial blood pressure was measured via a cannula introduced into the left carotid artery, and heart rate was counted from the pulse pressure. In all groups, diltiazem significantly decreased the mean arterial blood pressure without any changes in heart rate. Pretreatment with simvastatin and atorvastatin significantly enhanced the hypotensive effect of diltiazem, while that with pravastatin did not. Heart rate was not modified by pretreatment with the inhibitors. The results indicate that concomitant use of diltiazem with simvastatin or atorvastatin enhances diltiazem-induced hypotension, probably by competitive inhibition of diltiazem metabolism with simvastatin and atorvastatin metabolisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676178     DOI: 10.1248/yakushi.121.761

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  3 in total

Review 1.  Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry.

Authors:  Beatrice Alexandra Golomb; Michael H Criqui; Halbert White; Joel E Dimsdale
Journal:  Arch Intern Med       Date:  2004-01-26

2.  Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.

Authors:  Dong-Hyun Choi; Cheng Li; Jun-Shik Choi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jul-Sep       Impact factor: 2.569

3.  Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study.

Authors:  Yi-Chun Wang; Tsung-Cheng Hsieh; Chu-Lin Chou; Jung-Lun Wu; Te-Chao Fang
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.